The Bacillary Postbiotics, Including 2-Undecanone, Suppress the Virulence of Pathogenic Microorganisms
Secreted molecules from probiotic <i>Bacilli</i> have often been considered potential pharmaceuticals to fight infections caused by bacterial or yeast pathogens. In the present study, we investigated the antagonistic potential of secreted probiotic filtrates (hereafter, postbiotics) deri...
Saved in:
Main Authors: | , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Secreted molecules from probiotic <i>Bacilli</i> have often been considered potential pharmaceuticals to fight infections caused by bacterial or yeast pathogens. In the present study, we investigated the antagonistic potential of secreted probiotic filtrates (hereafter, postbiotics) derived from <i>Lactobacillus plantarum</i> cells against pathogenic microorganisms, such as <i>Escherichia coli</i>, <i>Staphylococcus aureus</i>, and <i>Candida albicans</i>. We found that the postbiotics mitigate the biofilms of the tested pathogens with no notable effect on their planktonic growth. In addition, the postbiotics suppressed some virulence traits, for instance, the dendrite swarming motility of <i>E. coli</i> and yeast-to-hyphal switch in <i>C. albicans</i>. Further assays with an active constituent produced by the <i>L. plantarum</i> cells-2-undecanone revealed two significant findings: (i) 2-undecanone inhibits <i>C. albicans</i> biofilms and hyphae <i>in vitro</i> and in a <i>Caenorhabditis elegans</i> model, and (ii) it interacts specifically with Gln 58 amino acid residue of hyphal wall protein-1 (Hwp-1) in molecular docking analysis. The results suggest the targeted mode of antagonistic action of 2-undecanone against <i>C. albicans</i> biofilm. In total, the findings of the study depict an appealing strategy to use postbiotics, including specific ketone molecules, produced by <i>L. plantarum</i> for developing novel antibiofilm and anti-hyphal pharmaceuticals. |
---|---|
Item Description: | 10.3390/pharmaceutics14050962 1999-4923 |